GTCM
BPMC

Gyon Technologies Capital Management’s Blueprint Medicines BPMC Stock Holding History

Gyon Technologies Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,642
Closed -$2.64M – 304
2021
Q4 		$2.64M Buy
24,642
+4,147
+20% +$434K 0.49% 50
2021
Q3 		$2.11M Buy
+20,495
New +$1.91M 0.57% 52

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Gyon Technologies Capital Management's BPMC Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 24,642 shares — an estimated $2.64M sold.

Gyon Technologies Capital Management first reported a position in BPMC in Q3 2021 and held it in 2 quarters. The position peaked at $2.64M in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 24,642 Blueprint Medicines shares in Q1 2022, an estimated $2.64M.
  • Gyon Technologies Capital Management first reported a position in Blueprint Medicines in Q3 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Blueprint Medicines position peaked at $2.64M in Q4 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.